| Product Unit Size | Cost | Quantity | Stock |
|---|
Terazosin is a quinazoline compound that inhibits α1-adrenergic receptors, exhibiting antihypertensive, anti-metastatic, and anticancer activities. Terazosin is clinically used to treat benign prostatic hyperplasia (BPH) and hypertension. In prostate cells, terazosin increases activation of caspase 3 and induces apoptosis. In prostate cancer cells, this compound induces apoptosis and inhibits cellular proliferation, invasion, and migration.
| Cas No. | 70024-40-7 |
|---|---|
| Purity | ≥98% |
| Formula | C19H25N5O4 • HCl • 2H2O |
| Formula Wt. | 459.93 |
| Chemical Name | 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2- furoyl)piperazine monohydrochloride dihydrate |
| IUPAC Name | [4-(4-amino-6, 7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; hydron;chloride;dihydrate |
| Synonym | Heitrin, Hytracin, Hytrin, Hytrinex, Itrin, Urodie, Vasocard |
| Melting Point | 271-274°C |
| Solubility | Soluble in water (<1 mg/mL), DMSO (25 mg/mL), ethanol (<1 mg/mL), methanol, chloroform. |
| Appearance | A White to off White Powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Oelke M, Gericke A, Michel MC. Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opin Drug Saf. 2014 Sep;13(9):1187-97. PMID: 25073735.
Papadopoulos G, Vlachodimitropoulos D, Kyroudi A, et al. Terazosin treatment induces caspase-3 expression in the rat ventral prostate. J Clin Med Res. 2013 Apr;5(2):127-31. PMID: 23518907.
Tahmatzopoulos A, Rowland RG, Kyprianou N. The role of alpha-blockers in the management of prostate cancer. Expert Opin Pharmacother. 2004 Jun;5(6):1279-85. PMID: 15163273.
Tomoda F, Takata M, Yoshida K, et al. Hemodynamic and endocrinological effects of a new selective alpha 1-blocking agent, terazosin, in patients with essential hypertension. Results of long-term treatment. Am J Hypertens. 1989 Nov;2(11 Pt 1):834-9. PMID: 2574044.